Terns Pharmaceuticals Stock Total Debt
| TERN Stock | USD 5.79 0.08 1.40% |
Terns Pharmaceuticals fundamentals help investors to digest information that contributes to Terns Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Terns Stock. The fundamental analysis module provides a way to measure Terns Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Terns Pharmaceuticals stock.
Terns |
Terns Pharmaceuticals Company Total Debt Analysis
Terns Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Terns Pharmaceuticals Total Debt | 603 K |
Most of Terns Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Terns Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Terns Total Debt Historical Pattern
Today, most investors in Terns Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Terns Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Terns Pharmaceuticals total debt as a starting point in their analysis.
Terns Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Terns Pharmaceuticals has a Total Debt of 603 K. This is 99.98% lower than that of the Pharmaceuticals sector and 99.81% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.
Terns Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Terns Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics of similar companies.Terns Pharmaceuticals is currently under evaluation in total debt category among its peers.
Terns Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Terns Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Terns Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Terns Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Terns Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Terns Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Terns Pharmaceuticals' value.| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 1.6 M | Superstring Capital Management Lp | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.2 M | Fmr Inc | 2024-09-30 | 1.2 M | Great Point Partners Llc | 2024-06-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Driehaus Capital Management Llc | 2024-06-30 | 1.1 M | Bellevue Group Ag | 2024-09-30 | 1 M | Orbimed Advisors, Llc | 2024-06-30 | 7.6 M | Vivo Capital, Llc | 2024-09-30 | 6.9 M |
Terns Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 120.32 M | ||||
| Shares Outstanding | 84.94 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 97.72 % | ||||
| Number Of Shares Shorted | 4.54 M | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (102.27 M) | ||||
| Net Income | (90.21 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 603 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (67.39 M) | ||||
| Short Ratio | 3.40 X | ||||
| Earnings Per Share | (1.18) X | ||||
| Target Price | 18.19 | ||||
| Number Of Employees | 66 | ||||
| Beta | -0.33 | ||||
| Market Capitalization | 491.8 M | ||||
| Total Asset | 268.52 M | ||||
| Retained Earnings | (332.63 M) | ||||
| Working Capital | 255.49 M | ||||
| Net Asset | 268.52 M |
About Terns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Terns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
Moving against Terns Stock
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | KZR | Kezar Life Sciences | PairCorr |
| 0.49 | GILD | Gilead Sciences | PairCorr |
| 0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Terns Pharmaceuticals Piotroski F Score and Terns Pharmaceuticals Altman Z Score analysis. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.